Rockefeller Capital Management
JAZZ icon

Rockefeller Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Rockefeller Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$47.1M Sell
249,174
-15,882
-6% -$2.78M 0.08% 230
2025
Q4 		$45.1M Sell
265,056
-11,816
-4% -$1.81M 0.08% 228
2025
Q3 		$36.5M Sell
276,872
-4,010
-1% -$481K 0.07% 251
2025
Q2 		$29.8M Buy
280,882
+23,656
+9% +$2.57M 0.07% 277
2025
Q1 		$31.9M Buy
257,226
+6,816
+3% +$889K 0.08% 243
2024
Q4 		$30.8M Buy
250,410
+4,006
+2% +$472K 0.08% 240
2024
Q3 		$27.5M Buy
246,404
+3,307
+1% +$362K 0.07% 256
2024
Q2 		$25.9M Buy
243,097
+148,691
+158% +$16.3M 0.07% 249
2024
Q1 		$11.4M Buy
94,406
+15,413
+20% +$1.89M 0.03% 464
2023
Q4 		$9.72M Buy
78,993
+19,946
+34% +$2.49M 0.03% 469
2023
Q3 		$7.64M Buy
59,047
+1,944
+3% +$259K 0.03% 488
2023
Q2 		$7.08M Buy
57,103
+18,801
+49% +$2.53M 0.03% 521
2023
Q1 		$5.6M Sell
38,302
-508
-1% -$75.1K 0.02% 546
2022
Q4 		$6.18M Buy
38,810
+1,758
+5% +$258K 0.03% 487
2022
Q3 		$4.94M Sell
37,052
-338
-0.9% -$51.4K 0.03% 538
2022
Q2 		$5.83M Sell
37,390
-11,602
-24% -$1.79M 0.03% 478
2022
Q1 		$7.63M Sell
48,992
-3,532
-7% -$513K 0.04% 438
2021
Q4 		$6.69M Buy
52,524
+23,107
+79% +$3.04M 0.03% 461
2021
Q3 		$3.83M Buy
29,417
+13,324
+83% +$2.01M 0.02% 555
2021
Q2 		$2.86M Buy
16,093
+9,957
+162% +$1.72M 0.02% 624
2021
Q1 		$1.01M Buy
6,136
+54
+0.9% +$8.89K 0.01% 780
2020
Q4 		$1M Sell
6,082
-1,022
-14% -$152K 0.01% 689
2020
Q3 		$1.01M Hold
7,104
– – 0.01% 594
2020
Q2 		$784K Sell
7,104
-100
-1% -$11.1K 0.01% 594
2020
Q1 		$718K Sell
7,204
-944
-12% -$122K 0.01% 540
2019
Q4 		$1.22M Buy
8,148
+40
+0.5% +$5.44K 0.02% 417
2019
Q3 		$1.04M Buy
8,108
+322
+4% +$43.2K 0.01% 384
2019
Q2 		$1.11M Buy
7,786
+496
+7% +$66.7K 0.02% 331
2019
Q1 		$1.04M Buy
7,290
+3,230
+80% +$421K 0.01% 368
2018
Q4 		$503K Buy
+4,060
New +$602K 0.01% 321

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Rockefeller Capital Management's JAZZ Position: Q1 2026 in Review

Rockefeller Capital Management reduced its Jazz Pharmaceuticals (JAZZ) stake by 6% in Q1 2026, selling an estimated $2.78M and leaving 249,174 shares worth $47.1M. The position accounts for 0.08% of the portfolio, ranked #230.

Rockefeller Capital Management first reported a position in JAZZ in Q4 2018 and has held it in 30 quarters since. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Rockefeller Capital Management held 249,174 shares of Jazz Pharmaceuticals worth $47.1M as of Q1 2026.
  • Rockefeller Capital Management sold 15,882 Jazz Pharmaceuticals shares in Q1 2026, an estimated $2.78M.
  • Jazz Pharmaceuticals made up 0.08% of Rockefeller Capital Management's portfolio in Q1 2026, its #230 holding.
  • Rockefeller Capital Management first reported a position in Jazz Pharmaceuticals in Q4 2018 and has held it in 30 quarters since.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.